Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.

This article reviews treatment-induced sexual dysfunctions related to 5-alpha-reductase inhibitors and reports no new results; it highlights the need to better define and understand this controversial topic.

This study of FAERS data suggests that finasteride, particularly at the 1 mg dosage, is associated with a wide range of adverse effects not previously established in long-term studies, especially among younger men.

This review found that 5α-reductase inhibitors are associated with slightly increased rates of sexual dysfunction, gynecomastia, and mood disorders, but the true significance and persistence of these effects remain unclear.

In this study, there was no evidence that using 5α-reductase inhibitors for either short or long durations increased the risk of male breast cancer.

This study concluded that 5α-reductase inhibitors were associated with improved survival in men with bladder cancer, while α-blockers showed no effect.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

This review discusses sexual dysfunction as a side effect of α-blockers and 5-ARIs for BPH/LUTS, highlighting methodological flaws in existing studies and the need for more rigorous research.

This study suggests that 5-alpha reductase inhibitors may reduce invasive cancer features and improve survival in men undergoing radical cystectomy for high-grade urothelial carcinoma, although further research is needed to confirm these findings.

This study suggests that the use of 5α-reductase inhibitors in men may be associated with macular abnormalities, characterized by cystoid changes and foveal cavitation, potentially progressing to more severe defects.

In this study, 5-α reductase inhibitors were not significantly linked to increased rhabdomyolysis risk, but they may raise the risk of myopathy and myositis in men aged 66 and older.

This letter reports no new findings and discusses potential concerns regarding 5-alpha reductase inhibitors on lung function, suggesting a reason for discontinuation during the COVID-19 pandemic.

This study found that patients with non-muscle invasive bladder cancer who were treated with 5-alpha reductase inhibitors had lower recurrence rates and higher recurrence-free survival rates compared to untreated patients.

This study found no positive association between the use of 5α-reductase inhibitors and the risk of male breast cancer.

This meta-analysis concluded that 5α-reductase inhibitors may increase the risk of mild depression, particularly with dutasteride, in patients treated for benign prostatic hyperplasia and androgenic alopecia.

This study found that Finnish men using 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had improved disease-specific survival compared to non-users, suggesting potential benefits of the treatment.

This study explored the optimization of phytochemicals from Alstonia boonei to develop potential 5-alpha reductase inhibitors for Benign Prostatic Hyperplasia, finding promising analogs with enhanced binding affinity and stability compared to Finasteride, warranting further experimental validation.

This study on rats found that finasteride and dutasteride increased collagen density in penile tissues and caused changes in prostate cells, but did not significantly alter erectile pressures compared to controls.

Using finasteride for hair loss or prostate issues does not significantly raise the risk of erectile dysfunction.

The literature review concluded that while 5α-reductase inhibitors hold promise for managing prostate cancer, they raise significant safety concerns regarding their association with high-grade tumors and mortality, highlighting the need for careful consideration in their clinical use.

This study reported that a novel cationic liposome formulation for delivering encapsulated Cas9 protein and sgRNA successfully decreased SRD5α2 mRNA expression by 29.7% in vitro, suggesting a potential alternative treatment option for conditions like prostate cancer and benign prostatic hyperplasia without current drug side effects.

This study found that long-term use of 5α-reductase inhibitors is associated with improved overall survival in men with renal cell carcinoma, particularly those with low comorbidity not receiving surgery or systemic therapy, suggesting a potential role for androgen modulation in disease management.

Finasteride and dutasteride have little effect on Type 2 Diabetes risk.

This study reported that cognitive biopsy diagnosed prostate cancer in 44% of patients with at least one previous negative biopsy, with higher detection rates in lesions classified as PI-RADS 4 and 5.

This study found that 5-α reductase inhibitors do not significantly increase the risk of erectile dysfunction in men with benign prostatic hyperplasia or alopecia, although duration of benign prostatic hyperplasia may elevate risk.

This report from a consensus meeting concluded that while 5-alpha reductase inhibitors are beneficial for BPH treatment and prostate cancer risk reduction, their role in clinical practice should be more widely integrated into prostate management guidelines.

Long-term use of a certain medication can worsen erectile function in aged rats by damaging penile muscle cells.

This study found no statistically significant association between the use of 5α-reductase inhibitors and male breast cancer incidence.

This study suggests that the use of finasteride for benign prostate hyperplasia may increase the risk of osteoporosis diagnosis, particularly at higher doses.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.